CN119053627A - 抗her2/neu抗体及使用方法 - Google Patents

抗her2/neu抗体及使用方法 Download PDF

Info

Publication number
CN119053627A
CN119053627A CN202380027645.1A CN202380027645A CN119053627A CN 119053627 A CN119053627 A CN 119053627A CN 202380027645 A CN202380027645 A CN 202380027645A CN 119053627 A CN119053627 A CN 119053627A
Authority
CN
China
Prior art keywords
antibody
amino acid
polypeptide
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380027645.1A
Other languages
English (en)
Chinese (zh)
Inventor
富兰克林·帕斯
史蒂文·斯托伊斯
贾斯廷·伦费尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Martel Diagnostic Laboratory Co ltd
Original Assignee
Martel Diagnostic Laboratory Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martel Diagnostic Laboratory Co ltd filed Critical Martel Diagnostic Laboratory Co ltd
Publication of CN119053627A publication Critical patent/CN119053627A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN202380027645.1A 2022-02-09 2023-02-09 抗her2/neu抗体及使用方法 Pending CN119053627A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267755P 2022-02-09 2022-02-09
US63/267,755 2022-02-09
PCT/US2023/062260 WO2023154780A1 (en) 2022-02-09 2023-02-09 Anti-her2/neu antibodies and methods of use

Publications (1)

Publication Number Publication Date
CN119053627A true CN119053627A (zh) 2024-11-29

Family

ID=86054158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380027645.1A Pending CN119053627A (zh) 2022-02-09 2023-02-09 抗her2/neu抗体及使用方法

Country Status (5)

Country Link
US (1) US20250180565A1 (https=)
EP (1) EP4476265A1 (https=)
JP (1) JP2025506203A (https=)
CN (1) CN119053627A (https=)
WO (1) WO2023154780A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2022221877A2 (en) * 2021-04-16 2022-10-20 Martell Diagnostic Laboratories, Inc. Lateral flow analysis and breast cancer

Also Published As

Publication number Publication date
JP2025506203A (ja) 2025-03-07
EP4476265A1 (en) 2024-12-18
WO2023154780A1 (en) 2023-08-17
US20250180565A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
US9840551B2 (en) Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
CN116284382B (zh) 抗降钙素原抗体及其应用
CN116023489A (zh) 与NT-proBNP特异性结合的抗体以及其用途
JP7205691B2 (ja) 抗イヌプロカルシトニン抗体及びこれを用いた検査用キット
US20110312922A1 (en) EDTA Resistant S100A12 Complexes (ERAC)
US20240210403A1 (en) Lateral flow analysis and breast cancer
CN113045646B (zh) 抗新型冠状病毒SARS-CoV-2的抗体
JP7010833B2 (ja) Ｉｌ－２１抗体及びその使用
CN111936522B (zh) 新型抗胸苷激酶抗体
CN119053627A (zh) 抗her2/neu抗体及使用方法
KR20140067047A (ko) 대장암 또는 식도암의 검출용 마커 및 검사 방법
CN113150143A (zh) 一种用于检测血清中g17含量的配对抗体及其应用
CN109997043B (zh) 护理点测定法
CN111303289B (zh) 抗人Tn型糖基化MUC1抗体及其用途
JP2014115186A (ja) 胃癌、肺癌及び／又は食道癌の検出方法
CN106053825B (zh) 标定试剂和方法
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
US20210024644A1 (en) N-cadherin binding molecules and uses thereof
CN119667163B (zh) Il-1r2在鉴定对象免疫状态中的应用
EP4509526A2 (en) Anti-thyroglobulin antibody, kit and use thereof
US11255856B2 (en) Immunoassay for detecting tumor pyruvate kinase M2
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
JP2004198313A (ja) 甲状腺腫瘍の診断用キット
KR20200049387A (ko) 브루셀라균의 omp28에 특이적으로 결합하는 단일클론항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
KR20190139289A (ko) 분석 및 치료 방법과 조성물, 그리고 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination